International Journal of Clinical Research

Objective To analyze the effect of intravenous thrombolysis with alteplase in the treatment of patients with early cerebral infarction. Methods A total of 141 patients with hyperacute cerebral infarction admitted from August 2024 to August 2025 were selected and randomly grouped by the envelope method. Patients in the control group received conventional treatment (non-thrombolytic therapy); Patients in the observation group were treated with intravenous thrombolysis with alteplase on this basis. The effective rate of treatment, stroke scale score and quality of life scale score of the two groups were compared. Results (1) The total effective rate of treatment in the observation group was 96.77%, which was higher than 86.67% in the control group (P < 0.05); (2) The PV, FIB and CRP in both groups decreased compared with those before treatment. In the comparison between the groups, the values of the three indicators in the observation group were all lower than those in the control group (P < 0.05). (3) The NIHSS scores of both groups decreased compared with before, and the decrease in the observation group was greater than that in the control group (P < 0.001). Conclusion Intravenous thrombolysis with alteplase in the treatment of early cerebral infarction can significantly improve the clinical efficacy, enhance the impaired neurological function and related index levels, and is worthy of promotion.

Urokinase (alteplase); Intravenous thrombolytic therapy; Early cerebral infarction; Neurological function; Quality of life